Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) Stock Competitors & Peer Comparison
See DMII's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMII and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMII | $10.23 | -0.00% | 652M | 73.11 | $0.14 | N/A |
| FRHC | $165.47 | -5.23% | 10.6B | 65.92 | $2.51 | N/A |
| RILYK | $25.23 | +0.16% | 787.6M | N/A | N/A | N/A |
| RILYM | $25.11 | +0.00% | 753M | N/A | N/A | N/A |
| DMIIU | $10.25 | -0.10% | 650.7M | 50.34 | $0.20 | N/A |
| RILYO | $25.13 | -0.02% | 573.5M | N/A | N/A | N/A |
| VACHU | $14.50 | +0.00% | 475.5M | N/A | N/A | N/A |
| LEGT-UN | $18.00 | +0.90% | 467.4M | N/A | N/A | N/A |
| TMS | $5.73 | +11.70% | 424M | N/A | N/A | N/A |
| CHAD | $10.00 | +0.16% | 326.2M | -1.52 | -$6.59 | N/A |
Stock Comparison
Freedom Holding Corp. (NASDAQ: FRHC)
DMII vs FRHC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, FRHC has a market cap of 10.6B. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while FRHC trades at $165.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas FRHC's P/E ratio is 65.92. In terms of profitability, DMII's ROE is +0.03%, compared to FRHC's ROE of +0.11%. Regarding short-term risk, DMII is less volatile compared to FRHC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FRHC's competition here
B. Riley Financial, Inc. 5.50% Senior Notes Due 2026 (NASDAQ: RILYK)
DMII vs RILYK Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYK has a market cap of 787.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYK trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYK's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYK's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYK. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYK's competition here
B. Riley Financial, Inc. - 6.37 (NASDAQ: RILYM)
DMII vs RILYM Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYM trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYM's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYM's ROE of +94.15%. Regarding short-term risk, DMII is more volatile compared to RILYM. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYM's competition here
Drugs Made In America Acquisition II Corp. Unit (NASDAQ: DMIIU)
DMII vs DMIIU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, DMIIU has a market cap of 650.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while DMIIU trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas DMIIU's P/E ratio is 50.34. In terms of profitability, DMII's ROE is +0.03%, compared to DMIIU's ROE of +0.03%. Regarding short-term risk, DMII is more volatile compared to DMIIU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check DMIIU's competition here
B. Riley Financial, Inc. - 6.75 (NASDAQ: RILYO)
DMII vs RILYO Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYO trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYO's ROE of +94.15%. Regarding short-term risk, DMII is more volatile compared to RILYO. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYO's competition here
Voyager Acquisition Corp. (NASDAQ: VACHU)
DMII vs VACHU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VACHU has a market cap of 475.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VACHU trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VACHU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VACHU's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to VACHU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VACHU's competition here
Legato Merger Corp. III (AMEX: LEGT-UN)
DMII vs LEGT-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, LEGT-UN has a market cap of 467.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while LEGT-UN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas LEGT-UN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT-UN's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT-UN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT-UN's competition here
Teamshares Inc. (NASDAQ: TMS)
DMII vs TMS Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, TMS has a market cap of 424M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while TMS trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas TMS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TMS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TMS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TMS's competition here
DeFi Development Corp. (NASDAQ: CHAD)
DMII vs CHAD Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CHAD has a market cap of 326.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CHAD trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CHAD's P/E ratio is -1.52. In terms of profitability, DMII's ROE is +0.03%, compared to CHAD's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to CHAD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CHAD's competition here
Safeguard Acquisition Corp. (NYSE: SAC)
DMII vs SAC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, SAC has a market cap of 317.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while SAC trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas SAC's P/E ratio is 80.13. In terms of profitability, DMII's ROE is +0.03%, compared to SAC's ROE of -0.52%. Regarding short-term risk, DMII is more volatile compared to SAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check SAC's competition here
Velos Acquisition I Corp. Units Cons of 1 Sh + 1/2 Red Wt (NASDAQ: VLOSU)
DMII vs VLOSU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VLOSU has a market cap of 310.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VLOSU trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VLOSU's P/E ratio is 95.58. In terms of profitability, DMII's ROE is +0.03%, compared to VLOSU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to VLOSU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check VLOSU's competition here
Velos Acquisition I Corp. (NASDAQ: VLOS)
DMII vs VLOS Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VLOS has a market cap of 309.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VLOS trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VLOS's P/E ratio is 95.09. In terms of profitability, DMII's ROE is +0.03%, compared to VLOS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to VLOS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VLOS's competition here
BRC Group Holdings, Inc. 6.50% Senior Notes Due 2026 (NASDAQ: RILYN)
DMII vs RILYN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYN has a market cap of 295.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYN trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYN's P/E ratio is 2.30. In terms of profitability, DMII's ROE is +0.03%, compared to RILYN's ROE of +94.15%. Regarding short-term risk, DMII is more volatile compared to RILYN. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYN's competition here
Cantor Equity Partners II, Inc. (NASDAQ: CEPT)
DMII vs CEPT Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CEPT has a market cap of 289.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CEPT trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CEPT's P/E ratio is -107.09. In terms of profitability, DMII's ROE is +0.03%, compared to CEPT's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to CEPT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CEPT's competition here
Evernorth Holdings, Inc. Class A (NASDAQ: XRPN)
DMII vs XRPN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, XRPN has a market cap of 279.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while XRPN trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas XRPN's P/E ratio is 81.56. In terms of profitability, DMII's ROE is +0.03%, compared to XRPN's ROE of -0.24%. Regarding short-term risk, DMII is less volatile compared to XRPN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check XRPN's competition here
NewHold Investment Corp IV Class A Ordinary Shares (NASDAQ: NHIV)
DMII vs NHIV Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, NHIV has a market cap of 273.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while NHIV trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas NHIV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIV's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to NHIV. This indicates higher risk in terms of short-term price fluctuations for DMII.Check NHIV's competition here
Mountain Lake Acquisition Corp. II Class A Ordinary Shares (NASDAQ: MLAA)
DMII vs MLAA Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, MLAA has a market cap of 261.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while MLAA trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas MLAA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MLAA's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to MLAA. This indicates higher risk in terms of short-term price fluctuations for DMII.Check MLAA's competition here
Keystone Acquisition Corp. Unit (NASDAQ: KEYYU)
DMII vs KEYYU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, KEYYU has a market cap of 254.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while KEYYU trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas KEYYU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to KEYYU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to KEYYU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check KEYYU's competition here
OneIM Acquisition Corp. Warrant (NASDAQ: OIMAW)
DMII vs OIMAW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, OIMAW has a market cap of 250M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while OIMAW trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas OIMAW's P/E ratio is -437.50. In terms of profitability, DMII's ROE is +0.03%, compared to OIMAW's ROE of -0.57%. Regarding short-term risk, DMII is less volatile compared to OIMAW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OIMAW's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBU)
DMII vs DRDBU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, DRDBU has a market cap of 247.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while DRDBU trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas DRDBU's P/E ratio is 60.27. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBU's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDBU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDBU's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDB)
DMII vs DRDB Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, DRDB has a market cap of 247.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while DRDB trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas DRDB's P/E ratio is 60.49. In terms of profitability, DMII's ROE is +0.03%, compared to DRDB's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDB. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDB's competition here
Evernorth Holdings Inc. Wt (NASDAQ: XRPNW)
DMII vs XRPNW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, XRPNW has a market cap of 244.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while XRPNW trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas XRPNW's P/E ratio is 11.99. In terms of profitability, DMII's ROE is +0.03%, compared to XRPNW's ROE of -0.24%. Regarding short-term risk, DMII is less volatile compared to XRPNW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check XRPNW's competition here
Inflection Point Acquisition Corp. VII Units Cons of 1 Shs A + 1/3 Red Wt (NASDAQ: IPXGU)
DMII vs IPXGU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, IPXGU has a market cap of 244.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while IPXGU trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas IPXGU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPXGU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPXGU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPXGU's competition here
Inflection Point Acquisition Corp. VII (NASDAQ: IPXG)
DMII vs IPXG Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, IPXG has a market cap of 242M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while IPXG trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas IPXG's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPXG's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPXG. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPXG's competition here
Illumination Acquisition Corp I Class A Ordinary Shares (NASDAQ: ILLU)
DMII vs ILLU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ILLU has a market cap of 236.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ILLU trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ILLU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLU's ROE of +0.05%. Regarding short-term risk, DMII is less volatile compared to ILLU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ILLU's competition here
Illumination Acquisition Corp I (NASDAQ: ILLUU)
DMII vs ILLUU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ILLUU has a market cap of 236.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ILLUU trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ILLUU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLUU's ROE of +0.05%. Regarding short-term risk, DMII is more volatile compared to ILLUU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check ILLUU's competition here
Bluerock Acquisition Corp. Class A Ordinary Shares (NASDAQ: BLRK)
DMII vs BLRK Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BLRK has a market cap of 233M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BLRK trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BLRK's P/E ratio is 85.77. In terms of profitability, DMII's ROE is +0.03%, compared to BLRK's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to BLRK. This indicates similar risk in terms of short-term price fluctuations for DMII.Check BLRK's competition here
Viking Acquisition Corp. II (NYSE: VII)
DMII vs VII Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VII has a market cap of 232.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VII trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VII's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VII's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to VII. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VII's competition here
TRG Latin America Acquisitions Corp. (NASDAQ: TRGSU)
DMII vs TRGSU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, TRGSU has a market cap of 215M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while TRGSU trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas TRGSU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TRGSU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TRGSU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TRGSU's competition here
Legato Merger Corp. III (AMEX: LEGT)
DMII vs LEGT Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, LEGT has a market cap of 214.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while LEGT trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas LEGT's P/E ratio is 32.83. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT's competition here
NewHold Investment Corp IV (NASDAQ: NHIVU)
DMII vs NHIVU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, NHIVU has a market cap of 214.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while NHIVU trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas NHIVU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIVU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to NHIVU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check NHIVU's competition here
Quantum Leap Acquisition Corp (NYSE: QLEP)
DMII vs QLEP Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, QLEP has a market cap of 212.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while QLEP trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas QLEP's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QLEP's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to QLEP. This indicates similar risk in terms of short-term price fluctuations for DMII.Check QLEP's competition here
Jones Ventures INTL Acquisition1 Corp (NASDAQ: JONEU)
DMII vs JONEU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, JONEU has a market cap of 209.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while JONEU trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas JONEU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JONEU's ROE of +7.88%. Regarding short-term risk, DMII is more volatile compared to JONEU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check JONEU's competition here
TRG Latin America Acquisitions Corp. Class A Ordinary Shares (NASDAQ: TRGS)
DMII vs TRGS Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, TRGS has a market cap of 208.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while TRGS trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas TRGS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TRGS's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to TRGS. This indicates higher risk in terms of short-term price fluctuations for DMII.Check TRGS's competition here
Safeguard Acquisition Corp. (NYSE: SAC-UN)
DMII vs SAC-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, SAC-UN has a market cap of 208M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while SAC-UN trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas SAC-UN's P/E ratio is 981.13. In terms of profitability, DMII's ROE is +0.03%, compared to SAC-UN's ROE of -0.52%. Regarding short-term risk, DMII is more volatile compared to SAC-UN. This indicates higher risk in terms of short-term price fluctuations for DMII.Check SAC-UN's competition here
Vendome Acquisition Corporation I (NASDAQ: VNME)
DMII vs VNME Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VNME has a market cap of 207.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VNME trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VNME's P/E ratio is 36.77. In terms of profitability, DMII's ROE is +0.03%, compared to VNME's ROE of +9.36%. Regarding short-term risk, DMII is less volatile compared to VNME. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNME's competition here
Vendome Acquisition Corporation I Warrant (NASDAQ: VNMEW)
DMII vs VNMEW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VNMEW has a market cap of 207.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VNMEW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VNMEW's P/E ratio is 0.71. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEW's ROE of +9.36%. Regarding short-term risk, DMII is less volatile compared to VNMEW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNMEW's competition here
Jones Ventures Intl Acquisition1 (NASDAQ: JONE)
DMII vs JONE Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, JONE has a market cap of 207.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while JONE trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas JONE's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JONE's ROE of +7.88%. Regarding short-term risk, DMII is less volatile compared to JONE. This indicates lower risk in terms of short-term price fluctuations for DMII.Check JONE's competition here
Vendome Acquisition Corporation I Unit (NASDAQ: VNMEU)
DMII vs VNMEU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VNMEU has a market cap of 206M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VNMEU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VNMEU's P/E ratio is 66.54. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEU's ROE of +9.36%. Regarding short-term risk, DMII is more volatile compared to VNMEU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check VNMEU's competition here
Interprivate Investment Partners V Inc. (NASDAQ: IPVV)
DMII vs IPVV Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, IPVV has a market cap of 204.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while IPVV trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas IPVV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPVV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPVV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPVV's competition here
Xterax Corporation II (NASDAQ: XTERU)
DMII vs XTERU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, XTERU has a market cap of 204.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while XTERU trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas XTERU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to XTERU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to XTERU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check XTERU's competition here
QDRO Acquisition Corp. Units (NASDAQ: QADRU)
DMII vs QADRU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, QADRU has a market cap of 203M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while QADRU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas QADRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QADRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to QADRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check QADRU's competition here
QDRO Acquisition Corp. Class A Ordinary Shares (NASDAQ: QADR)
DMII vs QADR Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, QADR has a market cap of 202.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while QADR trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas QADR's P/E ratio is 296.20. In terms of profitability, DMII's ROE is +0.03%, compared to QADR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to QADR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check QADR's competition here
Xterax Corporation II (NASDAQ: XTER)
DMII vs XTER Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, XTER has a market cap of 202.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while XTER trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas XTER's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to XTER's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to XTER. This indicates similar risk in terms of short-term price fluctuations for DMII.Check XTER's competition here
Meridian3 Ind S Acquisition Corp. (NASDAQ: MIAC)
DMII vs MIAC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, MIAC has a market cap of 199.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while MIAC trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas MIAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MIAC's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MIAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MIAC's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZ)
DMII vs BREZ Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BREZ has a market cap of 199.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BREZ trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BREZ's P/E ratio is 1654.10. In terms of profitability, DMII's ROE is +0.03%, compared to BREZ's ROE of +0.53%. Regarding short-term risk, DMII is more volatile compared to BREZ. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BREZ's competition here
InterPrivate Investment Partners V, Inc. Units (NASDAQ: IPVVU)
DMII vs IPVVU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, IPVVU has a market cap of 198.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while IPVVU trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas IPVVU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPVVU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPVVU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPVVU's competition here
Oceanhawk Acquisition Corp. Rights (NASDAQ: OHACR)
DMII vs OHACR Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, OHACR has a market cap of 189.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while OHACR trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas OHACR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHACR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OHACR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OHACR's competition here
Oceanhawk Acquisition Corp. Class A Ordinary Shares (NASDAQ: OHAC)
DMII vs OHAC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, OHAC has a market cap of 189.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while OHAC trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas OHAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHAC's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to OHAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check OHAC's competition here
JAB Acquisition Corp. I Class A (NASDAQ: ATLQ)
DMII vs ATLQ Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ATLQ has a market cap of 187.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ATLQ trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ATLQ's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ATLQ's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to ATLQ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ATLQ's competition here
Dynamix Corporation (NASDAQ: ETHM)
DMII vs ETHM Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ETHM has a market cap of 182.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ETHM trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ETHM's P/E ratio is -62.83. In terms of profitability, DMII's ROE is +0.03%, compared to ETHM's ROE of +0.62%. Regarding short-term risk, DMII is less volatile compared to ETHM. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ETHM's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBW)
DMII vs DRDBW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, DRDBW has a market cap of 179.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while DRDBW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas DRDBW's P/E ratio is 0.40. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDBW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDBW's competition here
JAB Acquisition Corp. I Units Cons of 1 Sh -A- + 1 Red Wt + 1 Rt (NASDAQ: ATLQU)
DMII vs ATLQU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ATLQU has a market cap of 177.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ATLQU trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ATLQU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ATLQU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to ATLQU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check ATLQU's competition here
Bluerock Acquisition Corp. (NASDAQ: BLRKU)
DMII vs BLRKU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BLRKU has a market cap of 175.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BLRKU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BLRKU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BLRKU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to BLRKU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BLRKU's competition here
Viking Acquisition Corp. I (NYSE: VACI-UN)
DMII vs VACI-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, VACI-UN has a market cap of 174.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while VACI-UN trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas VACI-UN's P/E ratio is 85.59. In terms of profitability, DMII's ROE is +0.03%, compared to VACI-UN's ROE of +0.01%. Regarding short-term risk, DMII is more volatile compared to VACI-UN. This indicates higher risk in terms of short-term price fluctuations for DMII.Check VACI-UN's competition here
Jab Acquisition Corp. I (NASDAQ: JAB)
DMII vs JAB Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, JAB has a market cap of 174.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while JAB trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas JAB's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JAB's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to JAB. This indicates lower risk in terms of short-term price fluctuations for DMII.Check JAB's competition here
Long Table Growth Corp. Units (NASDAQ: LTGRU)
DMII vs LTGRU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, LTGRU has a market cap of 173.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while LTGRU trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas LTGRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to LTGRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LTGRU's competition here
Long Table Growth Corp. (NASDAQ: LTGR)
DMII vs LTGR Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, LTGR has a market cap of 172.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while LTGR trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas LTGR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGR's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to LTGR. This indicates higher risk in terms of short-term price fluctuations for DMII.Check LTGR's competition here
Texas Ventures Acquisition IV Corp. (NASDAQ: TVIV)
DMII vs TVIV Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, TVIV has a market cap of 171.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while TVIV trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas TVIV's P/E ratio is -5852.94. In terms of profitability, DMII's ROE is +0.03%, compared to TVIV's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to TVIV. This indicates higher risk in terms of short-term price fluctuations for DMII.Check TVIV's competition here
Collective Acquisition Corp. (NASDAQ: CCAQU)
DMII vs CCAQU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CCAQU has a market cap of 159.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CCAQU trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CCAQU's P/E ratio is 60.47. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQU's ROE of +0.03%. Regarding short-term risk, DMII is more volatile compared to CCAQU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check CCAQU's competition here
Meridian3 Industrials Aquisition Corp Warrant (NASDAQ: MIACW)
DMII vs MIACW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, MIACW has a market cap of 159.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while MIACW trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas MIACW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MIACW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MIACW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MIACW's competition here
Arc Group Securities Acquisition I (NASDAQ: FJDIU)
DMII vs FJDIU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, FJDIU has a market cap of 157.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while FJDIU trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas FJDIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FJDIU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to FJDIU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check FJDIU's competition here
Ocean Capital Acquisition Corporation (NYSE: OCAC)
DMII vs OCAC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, OCAC has a market cap of 156.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while OCAC trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas OCAC's P/E ratio is -692.05. In terms of profitability, DMII's ROE is +0.03%, compared to OCAC's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to OCAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check OCAC's competition here
Collective Acquisition Corp. (NASDAQ: CCAQ)
DMII vs CCAQ Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CCAQ has a market cap of 156.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CCAQ trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CCAQ's P/E ratio is 58.78. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQ's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to CCAQ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCAQ's competition here
Graf Global Corp. (AMEX: TONT)
DMII vs TONT Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, TONT has a market cap of 155.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while TONT trades at $10.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas TONT's P/E ratio is 61.46. In terms of profitability, DMII's ROE is +0.03%, compared to TONT's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TONT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TONT's competition here
BRC Group Holdings Inc. 5% Sr. Notes due 2026 (NASDAQ: RILYG)
DMII vs RILYG Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYG has a market cap of 154.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYG trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYG's P/E ratio is 4.66. In terms of profitability, DMII's ROE is +0.03%, compared to RILYG's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYG. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYG's competition here
Social Capital Hedosophia Holdings Corp. IV (NASDAQ: IPOD)
DMII vs IPOD Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, IPOD has a market cap of 154.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while IPOD trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas IPOD's P/E ratio is 58.12. In terms of profitability, DMII's ROE is +0.03%, compared to IPOD's ROE of +0.05%. Regarding short-term risk, DMII is less volatile compared to IPOD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPOD's competition here
BRC Group Holdings Inc. 5.25% Sr. Notes due 2028 (NASDAQ: RILYZ)
DMII vs RILYZ Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYZ has a market cap of 153.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYZ trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYZ's P/E ratio is 3.11. In terms of profitability, DMII's ROE is +0.03%, compared to RILYZ's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYZ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYZ's competition here
Black Spade Acquisition II Co (NASDAQ: BSIIU)
DMII vs BSIIU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BSIIU has a market cap of 152.8M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BSIIU trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BSIIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BSIIU's ROE of -266.79%. Regarding short-term risk, DMII is more volatile compared to BSIIU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BSIIU's competition here
JAB Acquisition Corp I (NASDAQ: JABRU)
DMII vs JABRU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, JABRU has a market cap of 152.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while JABRU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas JABRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JABRU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to JABRU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check JABRU's competition here
B. Riley Financial, Inc. 6.00% Senior Notes Due 2028 (NASDAQ: RILYT)
DMII vs RILYT Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYT has a market cap of 152.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYT trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYT's P/E ratio is 3.53. In terms of profitability, DMII's ROE is +0.03%, compared to RILYT's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYT's competition here
SPACCircle Acquisition Corp. (NASDAQ: SCQCU)
DMII vs SCQCU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, SCQCU has a market cap of 150.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while SCQCU trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas SCQCU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SCQCU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to SCQCU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SCQCU's competition here
Forefront Tech Holdings Acquisition Corp Unit (NASDAQ: FTHAU)
DMII vs FTHAU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, FTHAU has a market cap of 148.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while FTHAU trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas FTHAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FTHAU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to FTHAU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check FTHAU's competition here
BRC Group Holdings, Inc. (NASDAQ: RILY)
DMII vs RILY Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILY has a market cap of 147.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILY trades at $3.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILY's P/E ratio is 0.29. In terms of profitability, DMII's ROE is +0.03%, compared to RILY's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILY. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILY's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCO)
DMII vs NCO Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, NCO has a market cap of 146.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while NCO trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas NCO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCO's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to NCO. This indicates higher risk in terms of short-term price fluctuations for DMII.Check NCO's competition here
BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock (NASDAQ: RILYL)
DMII vs RILYL Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYL has a market cap of 146.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYL trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYL's P/E ratio is 0.46. In terms of profitability, DMII's ROE is +0.03%, compared to RILYL's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYL. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYL's competition here
BRC Group Holdings, Inc. (NASDAQ: RILYP)
DMII vs RILYP Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RILYP has a market cap of 140.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RILYP trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RILYP's P/E ratio is 0.43. In terms of profitability, DMII's ROE is +0.03%, compared to RILYP's ROE of +94.15%. Regarding short-term risk, DMII is less volatile compared to RILYP. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYP's competition here
Social Commerce Partners Corporation (NASDAQ: SCPQW)
DMII vs SCPQW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, SCPQW has a market cap of 138.5M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while SCPQW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas SCPQW's P/E ratio is 4.92. In terms of profitability, DMII's ROE is +0.03%, compared to SCPQW's ROE of +0.02%. Regarding short-term risk, DMII is more volatile compared to SCPQW. This indicates higher risk in terms of short-term price fluctuations for DMII.Check SCPQW's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZR)
DMII vs BREZR Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BREZR has a market cap of 130.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BREZR trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BREZR's P/E ratio is 40.16. In terms of profitability, DMII's ROE is +0.03%, compared to BREZR's ROE of +0.53%. Regarding short-term risk, DMII is less volatile compared to BREZR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BREZR's competition here
East West Ave Acquisition Corp. Common Stock (NASDAQ: EWAV)
DMII vs EWAV Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, EWAV has a market cap of 127.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while EWAV trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas EWAV's P/E ratio is -14200.00. In terms of profitability, DMII's ROE is +0.03%, compared to EWAV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to EWAV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check EWAV's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCOOU)
DMII vs NCOOU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, NCOOU has a market cap of 119M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while NCOOU trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas NCOOU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCOOU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to NCOOU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check NCOOU's competition here
Plutonian Acquisition Corp II (NYSE: PLUN)
DMII vs PLUN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, PLUN has a market cap of 115.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while PLUN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas PLUN's P/E ratio is 337.67. In terms of profitability, DMII's ROE is +0.03%, compared to PLUN's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to PLUN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check PLUN's competition here
Shepherd Ave Capital Acquisition Corporation (NASDAQ: SPHA)
DMII vs SPHA Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, SPHA has a market cap of 111.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while SPHA trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas SPHA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SPHA's ROE of -1.30%. Regarding short-term risk, DMII is less volatile compared to SPHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SPHA's competition here
Arc Group Securities Acquisition I (NASDAQ: FJDI)
DMII vs FJDI Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, FJDI has a market cap of 110.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while FJDI trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas FJDI's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FJDI's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to FJDI. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FJDI's competition here
Enhanced Group Inc. Class A (NYSE: ENHA)
DMII vs ENHA Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, ENHA has a market cap of 106.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while ENHA trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas ENHA's P/E ratio is -28.74. In terms of profitability, DMII's ROE is +0.03%, compared to ENHA's ROE of -3.98%. Regarding short-term risk, DMII is less volatile compared to ENHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ENHA's competition here
Amanat Acquisition Corp Class A Ordinary Shares (NASDAQ: AMAN)
DMII vs AMAN Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, AMAN has a market cap of 97.9M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while AMAN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas AMAN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AMAN's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to AMAN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AMAN's competition here
Cayson Acquisition Corp (NASDAQ: CAPNU)
DMII vs CAPNU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CAPNU has a market cap of 94M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CAPNU trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CAPNU's P/E ratio is 56.23. In terms of profitability, DMII's ROE is +0.03%, compared to CAPNU's ROE of +0.03%. Regarding short-term risk, DMII is more volatile compared to CAPNU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check CAPNU's competition here
FTAC Emerald Acquisition Corp. (NASDAQ: FLDD)
DMII vs FLDD Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, FLDD has a market cap of 85.6M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while FLDD trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas FLDD's P/E ratio is -75.13. In terms of profitability, DMII's ROE is +0.03%, compared to FLDD's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to FLDD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FLDD's competition here
Research Alliance Corp. Iv (NASDAQ: RACD)
DMII vs RACD Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, RACD has a market cap of 81.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while RACD trades at $10.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas RACD's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RACD's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to RACD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RACD's competition here
Armada Acquisition Corp. III (NASDAQ: AACIU)
DMII vs AACIU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, AACIU has a market cap of 75.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while AACIU trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas AACIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AACIU's ROE of -0.24%. Regarding short-term risk, DMII is less volatile compared to AACIU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AACIU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQW)
DMII vs CCAQW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CCAQW has a market cap of 66.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CCAQW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CCAQW's P/E ratio is 0.66. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQW's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to CCAQW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCAQW's competition here
Bayview Acquisition Corp Unit (NASDAQ: BAYAU)
DMII vs BAYAU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BAYAU has a market cap of 63.1M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BAYAU trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BAYAU's P/E ratio is 258.06. In terms of profitability, DMII's ROE is +0.03%, compared to BAYAU's ROE of -0.03%. Regarding short-term risk, DMII is less volatile compared to BAYAU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BAYAU's competition here
Blueport Acquisition Ltd (NASDAQ: BPACU)
DMII vs BPACU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BPACU has a market cap of 61.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BPACU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BPACU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BPACU's ROE of +0.01%. Regarding short-term risk, DMII is more volatile compared to BPACU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BPACU's competition here
Blueport Acquisition Ltd (NASDAQ: BPAC)
DMII vs BPAC Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, BPAC has a market cap of 61.2M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while BPAC trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas BPAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BPAC's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to BPAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BPAC's competition here
Cartesian Growth Corporation III (NASDAQ: CGCTW)
DMII vs CGCTW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, CGCTW has a market cap of 50.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while CGCTW trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas CGCTW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CGCTW's ROE of -0.15%. Regarding short-term risk, DMII is less volatile compared to CGCTW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CGCTW's competition here
Horizon Quantum Holdings Ltd. Warrant (NASDAQ: HQWWW)
DMII vs HQWWW Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, HQWWW has a market cap of 50.3M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while HQWWW trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas HQWWW's P/E ratio is -1.56. In terms of profitability, DMII's ROE is +0.03%, compared to HQWWW's ROE of -2.97%. Regarding short-term risk, DMII is less volatile compared to HQWWW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HQWWW's competition here
YHN Acquisition I Limited (NASDAQ: YHNA)
DMII vs YHNA Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, YHNA has a market cap of 47.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while YHNA trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas YHNA's P/E ratio is 85.54. In terms of profitability, DMII's ROE is +0.03%, compared to YHNA's ROE of +0.10%. Regarding short-term risk, DMII is less volatile compared to YHNA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check YHNA's competition here
YHN Acquisition I Limited Unit (NASDAQ: YHNAU)
DMII vs YHNAU Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, YHNAU has a market cap of 47.7M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while YHNAU trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas YHNAU's P/E ratio is 551.74. In terms of profitability, DMII's ROE is +0.03%, compared to YHNAU's ROE of +0.10%. Regarding short-term risk, DMII is less volatile compared to YHNAU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check YHNAU's competition here
Horizon Space Acquisition II Corp. (NASDAQ: HSPT)
DMII vs HSPT Comparison November 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 652M. In comparison, HSPT has a market cap of 46.4M. Regarding current trading prices, DMII is priced at $10.23 on the NASDAQ, while HSPT trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 73.11, whereas HSPT's P/E ratio is 41.86. In terms of profitability, DMII's ROE is +0.03%, compared to HSPT's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to HSPT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HSPT's competition here